E. Ohman J or Asset Management AB Has $2.32 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

E. Ohman J or Asset Management AB lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.9% in the first quarter, Holdings Channel.com reports. The firm owned 23,734 shares of the medical equipment provider’s stock after selling 450 shares during the period. E. Ohman J or Asset Management AB’s holdings in Lantheus were worth $2,316,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Silverberg Bernstein Capital Management LLC boosted its stake in Lantheus by 5.0% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 21,129 shares of the medical equipment provider’s stock valued at $2,062,000 after purchasing an additional 1,000 shares during the last quarter. Rhumbline Advisers boosted its stake in Lantheus by 1.7% during the 1st quarter. Rhumbline Advisers now owns 216,296 shares of the medical equipment provider’s stock valued at $21,110,000 after purchasing an additional 3,623 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in Lantheus during the 1st quarter valued at about $207,000. J2 Capital Management Inc acquired a new position in Lantheus during the 1st quarter valued at about $397,000. Finally, GAMMA Investing LLC boosted its stake in Lantheus by 12,517.1% during the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider’s stock valued at $12,536,000 after purchasing an additional 127,424 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 1.5%

Lantheus stock opened at $81.55 on Friday. Lantheus Holdings, Inc. has a 52 week low of $73.11 and a 52 week high of $126.89. The company’s 50 day moving average price is $90.26 and its two-hundred day moving average price is $91.67. The stock has a market cap of $5.64 billion, a P/E ratio of 13.57 and a beta of 0.11.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same period in the prior year, the business earned $1.69 EPS. Lantheus’s quarterly revenue was up .8% compared to the same quarter last year. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director now owns 318,650 shares of the company’s stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,068 shares of company stock valued at $3,008,051. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. B. Riley cut their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $132.67.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.